Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
Main Authors: | Jan Olof G. Karlsson, Per Jynge, Ingemar Lundström, Louis J. Ignarro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Trials |
Online Access: | http://link.springer.com/article/10.1186/s13063-019-3476-3 |
Similar Items
-
Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose—the PP100–01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial
by: The POP Trial Investigators, et al.
Published: (2019-01-01) -
Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial)Research in context
by: Emma E. Morrison, et al.
Published: (2019-08-01) -
Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose
by: Janice M. Pettie, et al.
Published: (2019-05-01) -
Efficacy of a two bag acetylcysteine regimen to treat paracetamol overdose (2NAC study)
by: Anselm Wong, et al.
Published: (2020-03-01) -
Delayed presentation of paracetamol overdose
by: Johnre Retief Els, et al.
Published: (2020-09-01)